At the current state, all this remains speculative and further studies are needed to preclinically validate the therapeutic efficacy of CCL20/CCR6 inhibitors in CF and to define the particular relevance of CCR6-expressing blood-derived ILC2s in this context. This evidence concerns the gene CCR6 and cystic fibrosis.